Biological agents, such as multikinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors, have replaced immunotherapy as the standard of care for metastatic renal cell carcinoma (mRCC). Several clinical trials have been performed, aimed to identify new feasible therapeutic targets. AKT, PI3K, STAT3, NOTCH-1, α5β1-integrin, CD70 and G250 are just examples of these opening frontiers. Novel agents, combination and sequences are emerging from the 887 clinical studies presently in course in mRCC to optimize patient outcomes. This report not includes studies on chemotherapy, local approaches, immunotherapy, surgical trials and other categories, but provides an update on ongoing phase I, II and III trials and preliminary results on targeted agents, used alone, in sequences or in combination for mRCC.

Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming? / M., Santoni; M., Rizzo; L., Burattini; R., Berardi; G., Cartenì; Cascinu, Stefano. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - 13(3)(2012), pp. 313-325. [10.2174/1568009611313030009]

Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?

CASCINU, Stefano
2012

Abstract

Biological agents, such as multikinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors, have replaced immunotherapy as the standard of care for metastatic renal cell carcinoma (mRCC). Several clinical trials have been performed, aimed to identify new feasible therapeutic targets. AKT, PI3K, STAT3, NOTCH-1, α5β1-integrin, CD70 and G250 are just examples of these opening frontiers. Novel agents, combination and sequences are emerging from the 887 clinical studies presently in course in mRCC to optimize patient outcomes. This report not includes studies on chemotherapy, local approaches, immunotherapy, surgical trials and other categories, but provides an update on ongoing phase I, II and III trials and preliminary results on targeted agents, used alone, in sequences or in combination for mRCC.
13(3)
313
325
Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming? / M., Santoni; M., Rizzo; L., Burattini; R., Berardi; G., Cartenì; Cascinu, Stefano. - In: CURRENT CANCER DRUG TARGETS. - ISSN 1568-0096. - 13(3)(2012), pp. 313-325. [10.2174/1568009611313030009]
M., Santoni; M., Rizzo; L., Burattini; R., Berardi; G., Cartenì; Cascinu, Stefano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1079276
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact